Many of the conditions we see and treat daily have roots in lifestyle decisions and behaviours. With good preventative advice and support, perhaps we can help reduce their incidence.
Scientists from Arthritis Research Canada found a significant drop in all-cause mortality and major adverse cardiovascular events in people from the group who took glucagon-like peptide-1 receptor agonists.
For those at high risk of diabetes, a threshold of four years of maintaining non-diabetic status could reduce the risk of death and cardiovascular complications.
National Academies of Sciences, Engineering, and Medicine definition also includes characteristic symptoms, associated diagnosable conditions and important features.
Cohort study finds lower hazards of all-cause mortality, adverse cardiovascular events, acute kidney injury and adverse kidney events with tirzepatide versus GLP-1 RAs.